-
公开(公告)号：EP4253401A3
公开(公告)日：2023-11-22
申请号：EP23176827.6
申请日：2014-11-03
发明人： Weinschenk, Toni , Fritsche, Jens , Walter, Steffen , Hilf, Norbert , Schoor, Oliver , Singh, Harpreet , Kuttruff-Coqui, Sabrina , Song, Colette
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：EP3539979A3
公开(公告)日：2020-01-01
申请号：EP19166517.3
申请日：2014-11-03
发明人： Weinschenk, Toni , Fritsche, Jens , Walter, Steffen , Hilf, Norbert , Schoor, Oliver , Singh, Harpreet , Kuttruff-Coqui, Sabrina , Song, Colette
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
3.发明公开
公开(公告)号：EP3388077A1
公开(公告)日：2018-10-17
申请号：EP18174312.1
申请日：2016-03-24
发明人： Mahr, Andrea , Stevermann, Lea , Weinschenk, Toni , Schoor, Oliver , Fritsche, Jens , Singh, Harpreet
CPC分类号： C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
4.发明公开
公开(公告)号：EP3388076A1
公开(公告)日：2018-10-17
申请号：EP18174292.5
申请日：2016-03-24
发明人： Mahr, Andrea , Stevermann, Lea , Weinschenk, Toni , Schoor, Oliver , Fritsche, Jens , Singh, Harpreet
CPC分类号： C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
5.发明授权Novel immunotherapy against neuronal and brain tumors 有权Neuartige Immuntherapie gegen Nerven- und Hirntumore
公开(公告)号：EP2105501B1
公开(公告)日：2015-10-07
申请号：EP08005889.4
申请日：2008-03-27
发明人： Emmerich, Niels , Singh, Harpreet , Schoor Oliver , Hilf, Norbert , Weinschenk, Toni , Trautwein, Claudia , Walter, Steffen
CPC分类号： C07K14/4748
-
6.发明公开Novel immunotherapy against several tumors including gastrointestinal and gastric cancer 有权Neuartige Immuntherapie gegen verschiedene TumoreeinschließlichDarm- und Magenkrebs
公开(公告)号：EP2923708A1
公开(公告)日：2015-09-30
申请号：EP15154344.4
申请日：2011-03-15
CPC分类号： A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要翻译： 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽的组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的95种新型肽序列及其衍生自人类肿瘤细胞HLA I类分子的变体。
-
7.发明公开Novel immunotherapy against several tumors including gastrointestinal and gastric cancer 有权对几种肿瘤，包括胃肠和胃癌新颖免疫疗法
公开(公告)号：EP2845604A3
公开(公告)日：2015-05-20
申请号：EP14184348.2
申请日：2011-03-15
CPC分类号： A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
8.发明公开Novel immunogenic epitopes for immunotherapy 有权Neuartige immunogenetische Epitope zur Immuntherapie
公开(公告)号：EP2565204A1
公开(公告)日：2013-03-06
申请号：EP12191631.6
申请日：2008-07-25
发明人： Singh, Harpreet , Schoor, Oliver , Trautwein, Claudia , Hilf, Norbert , Weinschenk, Toni , Walter, Steffen , Lewandrowski, Peter
IPC分类号： C07K14/47 , A61K39/00 , C07K14/495
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to amino acid sequences of peptides derived from tumour associated antigens that are able to bind to MHC complexes of either class, and elicit an immune response, as well as to uses of said peptides for the treatment of diseases.
摘要翻译： 本发明涉及能够结合任一类MHC复合物并引发免疫应答的衍生自肿瘤相关抗原的肽的氨基酸序列，以及所述肽用于治疗疾病的用途。
-
公开(公告)号：EP2295443A1
公开(公告)日：2011-03-16
申请号：EP10009967.0
申请日：2004-03-23
发明人： Rammensee, Hans-Georg , Stevanovic, Stefan , Weinschenk, Toni , Trautwein, Claudia , Djengjel, Jörn , Schoor, Oliver
CPC分类号： C07K7/06 , A61K38/00 , C07K14/47 , C07K14/4748 , C07K14/78
摘要： Die Erfindung betrifft ein Tumor-assozüertes Peptid mit einer Aminosäuresequenz, die ausgewählt ist aus der Gruppe bestehend aus SEQ ID-Nr. 1 bis SEQ ID-Nr. 101 aus dem beiliegenden Sequenzprotokoll, wobei das Peptid die Fähigkeit aufweist, an ein Molekül des menschlichen Haupt-Histokompatibilitäts-Komplexes (MHC) Klasse-I zu binden. Die Erfindung betrifft darüber hinaus die Verwendung der Peptide und der für die Peptide kodierenden Nukleinsäuren zur Herstellung eines Arzneimittels und zur Behandlung von Tumorerkrankungen und/oder adenomatöser Erkrankungen. Ferner wird eine pharmazeutische Zusammensetzung beschrieben, die mindestens eines der Peptide aufweist.
摘要翻译： 101个特异性肿瘤相关肽（I），可以结合人类主要组织相容性复合体（MHC）I类分子的所有序列都是新的。 还包括：（1）编码（I）的核酸（II）; （2）含有（II）的载体; 和（3）由（II）转基因或（2）的载体产生（I）的细胞。 活动：细胞抑制。 没有给出生物数据。 动作机制：疫苗; 诱导细胞毒性T细胞应答，包括体外诱导，随后向患者施用活化细胞。
-
10.发明公开
公开(公告)号：EP4324472A2
公开(公告)日：2024-02-21
申请号：EP23216403.8
申请日：2016-08-05
发明人： Mahr, Andrea , Weinschenk, Toni , Schoor, Oliver , Fritsche, Jens , Singh, Harpreet , Müller, Phillip , Leibold, Julia , Goldfinger, Valentina
IPC分类号： A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumorassociated T-cell peptide epitopes, alone or in combination with other tumorassociated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
搜索结果
84 条记录 (耗时 0.045 秒)
